Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Active not recruiting 3Available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 1Lung Diseases 1

Interventions

Carboplatin 1167Cisplatin 889Pemetrexed 845pembrolizumab 622Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 124Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
zipalertinib × Thoracic × Clear all
NCT07601399 2026-05-22

An EAP Treatment Protocol of Zipalertinib

Taiho Oncology, Inc.

Available
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-05-05

REZILIENT4

Taiho Oncology, Inc.

Phase 3 Active not recruiting
360 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05973773 2026-03-10

REZILIENT3

Taiho Oncology, Inc.

Phase 3 Active not recruiting
285 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT04036682 2025-03-13

REZILIENT1

Cullinan Therapeutics Inc.

Phase 1/2 Active not recruiting
284 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡